Cargando…

A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus

BACKGROUND: Medicinal plants have long been used for the treatment of type 2 diabetes mellitus (T2DM). This study aimed to investigate the hypoglycemic efficacy and safety of NW Low-Glu® (contents of one capsule are 300 mg Mas Cotek + 100 mg Cinnamomum cassia L. + 250 mg Nigella sativa L. powdered e...

Descripción completa

Detalles Bibliográficos
Autores principales: Assaad-Khalil, Samir, Elkafrawy, Nabil, Khaled, Mohsen, Mogeib, Omneya, Badr, Hytham, Rashwan, Ahmed, Youssef, Mahmoud, Eltamawy, Khaled, Mohamed, Shahnaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532066/
https://www.ncbi.nlm.nih.gov/pubmed/36204125
http://dx.doi.org/10.1155/2022/9176026
_version_ 1784802032345939968
author Assaad-Khalil, Samir
Elkafrawy, Nabil
Khaled, Mohsen
Mogeib, Omneya
Badr, Hytham
Rashwan, Ahmed
Youssef, Mahmoud
Eltamawy, Khaled
Mohamed, Shahnaz
author_facet Assaad-Khalil, Samir
Elkafrawy, Nabil
Khaled, Mohsen
Mogeib, Omneya
Badr, Hytham
Rashwan, Ahmed
Youssef, Mahmoud
Eltamawy, Khaled
Mohamed, Shahnaz
author_sort Assaad-Khalil, Samir
collection PubMed
description BACKGROUND: Medicinal plants have long been used for the treatment of type 2 diabetes mellitus (T2DM). This study aimed to investigate the hypoglycemic efficacy and safety of NW Low-Glu® (contents of one capsule are 300 mg Mas Cotek + 100 mg Cinnamomum cassia L. + 250 mg Nigella sativa L. powdered extracts) in treatment-naïve, newly diagnosed T2DM patients. METHODS: This was a 12-week, double-blind, double-dummy, randomized, phase 2 clinical trial. A total of 232 male and female patients aged ≥18 and ≤65 years who were newly diagnosed with T2DM and have not received any antidiabetic drugs before and were equally randomized to receive metformin (2000 mg per day), low-dose NW Low-Glu® (content of four capsules per day), or high-dose NW Low-Glu® (content of five capsules per day). Our primary objective was to measure the mean change in HbA1c between each of the experimental arms and the metformin arm. RESULTS: There was a significant reduction in mean HbA1c at 12 weeks compared to baseline in the low-dose (0.6 (1.4)%; p=0.002) and high-dose arms (0.8 (1.7)%; p=0.004). There was also a significant reduction in 2 hr PPG at 12 weeks in the low-dose (35.4 (74.9) mg/dL, p=0.001) and high-dose arms (24.7 (100.8) mg/dL, p=0.04). Weight reduction was significantly higher with both high-dose (1.1 (−1.7) Kg; p=0.005) and low-dose arms (0.9 (−1.5) Kg; p=0.023) compared to metformin (0.8 (−1.8) Kg). No serious AEs or deaths were reported. CONCLUSIONS: After 3 months of treatment, NW Low-Glu® was noninferior to metformin in reducing HbA1c and 2 hr PPG, while leading to significantly higher weight reduction in newly diagnosed T2DM patients. It was also safe and well tolerated.
format Online
Article
Text
id pubmed-9532066
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-95320662022-10-05 A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus Assaad-Khalil, Samir Elkafrawy, Nabil Khaled, Mohsen Mogeib, Omneya Badr, Hytham Rashwan, Ahmed Youssef, Mahmoud Eltamawy, Khaled Mohamed, Shahnaz Evid Based Complement Alternat Med Research Article BACKGROUND: Medicinal plants have long been used for the treatment of type 2 diabetes mellitus (T2DM). This study aimed to investigate the hypoglycemic efficacy and safety of NW Low-Glu® (contents of one capsule are 300 mg Mas Cotek + 100 mg Cinnamomum cassia L. + 250 mg Nigella sativa L. powdered extracts) in treatment-naïve, newly diagnosed T2DM patients. METHODS: This was a 12-week, double-blind, double-dummy, randomized, phase 2 clinical trial. A total of 232 male and female patients aged ≥18 and ≤65 years who were newly diagnosed with T2DM and have not received any antidiabetic drugs before and were equally randomized to receive metformin (2000 mg per day), low-dose NW Low-Glu® (content of four capsules per day), or high-dose NW Low-Glu® (content of five capsules per day). Our primary objective was to measure the mean change in HbA1c between each of the experimental arms and the metformin arm. RESULTS: There was a significant reduction in mean HbA1c at 12 weeks compared to baseline in the low-dose (0.6 (1.4)%; p=0.002) and high-dose arms (0.8 (1.7)%; p=0.004). There was also a significant reduction in 2 hr PPG at 12 weeks in the low-dose (35.4 (74.9) mg/dL, p=0.001) and high-dose arms (24.7 (100.8) mg/dL, p=0.04). Weight reduction was significantly higher with both high-dose (1.1 (−1.7) Kg; p=0.005) and low-dose arms (0.9 (−1.5) Kg; p=0.023) compared to metformin (0.8 (−1.8) Kg). No serious AEs or deaths were reported. CONCLUSIONS: After 3 months of treatment, NW Low-Glu® was noninferior to metformin in reducing HbA1c and 2 hr PPG, while leading to significantly higher weight reduction in newly diagnosed T2DM patients. It was also safe and well tolerated. Hindawi 2022-09-27 /pmc/articles/PMC9532066/ /pubmed/36204125 http://dx.doi.org/10.1155/2022/9176026 Text en Copyright © 2022 Samir Assaad-Khalil et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Assaad-Khalil, Samir
Elkafrawy, Nabil
Khaled, Mohsen
Mogeib, Omneya
Badr, Hytham
Rashwan, Ahmed
Youssef, Mahmoud
Eltamawy, Khaled
Mohamed, Shahnaz
A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus
title A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus
title_full A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus
title_fullStr A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus
title_full_unstemmed A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus
title_short A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus
title_sort phase ii, randomized, double-blind, double-dummy, active-controlled clinical trial to investigate the efficacy and safety of nw low-glu® in patients newly diagnosed with type 2 diabetes mellitus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532066/
https://www.ncbi.nlm.nih.gov/pubmed/36204125
http://dx.doi.org/10.1155/2022/9176026
work_keys_str_mv AT assaadkhalilsamir aphaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT elkafrawynabil aphaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT khaledmohsen aphaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT mogeibomneya aphaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT badrhytham aphaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT rashwanahmed aphaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT youssefmahmoud aphaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT eltamawykhaled aphaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT mohamedshahnaz aphaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT assaadkhalilsamir phaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT elkafrawynabil phaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT khaledmohsen phaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT mogeibomneya phaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT badrhytham phaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT rashwanahmed phaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT youssefmahmoud phaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT eltamawykhaled phaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus
AT mohamedshahnaz phaseiirandomizeddoubleblinddoubledummyactivecontrolledclinicaltrialtoinvestigatetheefficacyandsafetyofnwlowgluinpatientsnewlydiagnosedwithtype2diabetesmellitus